Evaluating the Suitability of Dengue Viraemia as a Surrogate Efficacy Outcome for Phase III Trials of Dengue Antivirals: A Systematic Review
This systematic review concludes that dengue viraemia is an inconsistent and unvalidated surrogate efficacy outcome for Phase III trials due to methodological heterogeneity and a lack of evidence linking treatment-induced viral load reductions to clinical benefit, recommending it instead as a supportive pharmacodynamic biomarker for early-phase development.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Dengue fever is a mosquito-borne illness that has been spreading to new parts of the world, reaching record numbers of cases in recent years. While most people who catch the virus recover with just a fever and body aches, a small but dangerous fraction develop severe dengue, a condition where the body's blood vessels begin to leak, leading to shock and potentially death. For decades, doctors have relied on supportive care, such as fluids and monitoring, because there are no approved drugs to stop the virus itself. To find a cure, scientists need to run large clinical trials to test new medicines. However, because severe dengue is relatively rare compared to mild cases, running a trial large enough to prove a drug prevents the severe form would require thousands of participants and immense resources. This logistical hurdle has led researchers to wonder if they could use a simpler, faster measurement as a shortcut. Specifically, they asked if measuring the amount of virus in a patient's blood—known as viraemia—could serve as a reliable stand-in for the actual disease outcome. If a drug lowers the virus count quickly, could scientists assume it will also prevent the severe illness, allowing them to test new treatments much faster and with fewer people?
A team of researchers from the University of Oxford and other institutions set out to answer this question by looking at every available study that had measured the virus in the blood of dengue patients and tracked their recovery. They gathered data from eleven different studies conducted across Asia and the Pacific, involving hundreds of patients ranging from young children to adults. These studies had measured the virus using a highly sensitive technique that counts the genetic material of the dengue virus in blood samples taken at different times after a person first felt sick. The researchers wanted to see if a higher amount of virus in the blood consistently predicted that a patient would develop severe dengue, and if a drop in that virus count meant the patient was safe.
The investigation revealed a picture that was far more complicated than a simple cause-and-effect relationship. In some of the studies, patients who ended up with severe dengue did indeed have higher levels of virus in their blood during the first few days of illness compared to those who remained mild. In a few cases, researchers also noticed that patients whose virus levels dropped quickly were less likely to get sick. However, this pattern was not consistent across all the research. Several other studies found no clear link between how much virus was in the blood and how sick the patient became. Some patients with very high virus counts recovered without complications, while others with lower counts still developed severe symptoms. The researchers found that the timing of the blood test mattered immensely; because the virus levels change rapidly in the first few days of illness, a test taken even a day or two later could show a completely different picture. Furthermore, the studies used different definitions for what counted as "severe" dengue, and many did not account for other factors that influence the disease, such as the patient's age, whether they had been infected with dengue before, or which specific type of dengue virus was involved.
Because of these inconsistencies and the lack of studies designed to prove that lowering the virus actually prevents the severe disease, the team concluded that the evidence is too weak to use virus levels as a shortcut for testing new drugs. They determined that while measuring the virus is useful for understanding how a drug works in the early stages of development, it cannot yet replace the need to watch patients for the actual clinical outcome of severe illness. The relationship between the amount of virus in the blood and the severity of the disease is influenced by a complex web of factors involving the patient's immune system and the specific virus strain, meaning that simply reducing the virus count does not guarantee a better outcome. Consequently, the researchers advise that future large-scale trials for dengue antivirals must continue to use patient-centered outcomes, such as hospitalization or severe bleeding, as the primary measure of success, rather than relying on the virus count alone.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.